Spectrascience New Valuation
| SCIEDelisted Stock | USD 1.42 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Spectrascience New has a current Real Value of $0.92 per share. The regular price of the company is $1.42. Our model measures the value of Spectrascience New from inspecting the company fundamentals such as EBITDA of (1.99 M), price to earning of (0.04) X, and Return On Asset of -0.92 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Spectrascience New's price fluctuation is risky at this time. Calculation of the real value of Spectrascience New is based on 3 months time horizon. Increasing Spectrascience New's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Spectrascience stock is determined by what a typical buyer is willing to pay for full or partial control of Spectrascience New. Since Spectrascience New is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Spectrascience Stock. However, Spectrascience New's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.42 | Real 0.92 | Hype 1.42 | Naive 1.79 |
The real value of Spectrascience Stock, also known as its intrinsic value, is the underlying worth of Spectrascience New Company, which is reflected in its stock price. It is based on Spectrascience New's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Spectrascience New's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Spectrascience New helps investors to forecast how Spectrascience stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Spectrascience New more accurately as focusing exclusively on Spectrascience New's fundamentals will not take into account other important factors: Spectrascience New Total Value Analysis
Spectrascience New is at this time forecasted to have valuation of 492.38 K with market capitalization of 492.38 K, debt of 6.38 M, and cash on hands of 27.88 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Spectrascience New fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
492.38 K | 492.38 K | 6.38 M | 27.88 K |
Spectrascience New Investor Information
The company recorded a loss per share of 0.01. Spectrascience New had not issued any dividends in recent years. The entity had 1:100 split on the 18th of November 2003. Based on the key measurements obtained from Spectrascience New's financial statements, Spectrascience New is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Spectrascience New Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Spectrascience New has an asset utilization ratio of 0.37 percent. This indicates that the Company is making $0.003715 for each dollar of assets. An increasing asset utilization means that Spectrascience New is more efficient with each dollar of assets it utilizes for everyday operations.Spectrascience New Profitability Analysis
The company reported the previous year's revenue of 5.15 K. Net Loss for the year was (4.47 M) with loss before overhead, payroll, taxes, and interest of (196.44 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Spectrascience New's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Spectrascience New and how it compares across the competition.
About Spectrascience New Valuation
The delisted stock valuation mechanism determines Spectrascience New's current worth on a weekly basis. Our valuation model uses a comparative analysis of Spectrascience New. We calculate exposure to Spectrascience New's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Spectrascience New's related companies.SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California. Spectrascience operates under Medical Appliances Equipment classification in the United States and is traded on OTC Exchange. It employs 5 people.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Spectrascience Stock
If you are still planning to invest in Spectrascience New check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrascience New's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |